

**IN THE CLAIMS**

Please amend the claims as follows:

1. **(Original)** Crystalline compound of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has diffraction peaks at the diffraction angles (2θ) of:  $4.7 \pm 0.1^\circ$ ,  $7.4 \pm 0.1^\circ$ ,  $11.8 \pm 0.1^\circ$ ,  $13.4 \pm 0.1^\circ$ ,  $16.5 \pm 0.1^\circ$ , and  $18.6 \pm 0.1^\circ$  in a powder X-ray diffraction pattern.
2. **(Original)** The crystalline compound according to claim 1, which has endothermic peaks approximately at 170 – 190°C and 225°C in a DSC chart obtained in differential scanning calorimetry (DSC).
3. **(Currently amended)** A composition comprising the crystalline compound according to claim 1 ~~or 2~~.
4. **(Currently amended)** A pharmaceutical composition comprising the crystalline compound according to claim 1 ~~or 2~~.
5. **(Currently amended)** An antiallergic medicine comprising the crystalline compound according to claim 1 ~~or 2~~.
6. **(Currently amended)** Use of the crystalline compound according to claim 1 ~~or 2~~ for the production of a pharmaceutical composition.
7. **(Currently amended)** Use of the crystalline compound according to claim 1 ~~or 2~~ for the production of an antiallergic medicine.

8. **(Currently amended)** A method for preventing or treating an allergic disease, comprising administering the crystalline compound according to claim 1 ~~or 2~~ to an animal including a human.